161 related articles for article (PubMed ID: 9125861)
21. Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guérin for carcinoma in situ of the bladder.
Merz VW; Marth D; Kraft R; Ackermann DK; Zingg EJ; Studer UE
Br J Urol; 1995 Feb; 75(2):180-4. PubMed ID: 7850322
[TBL] [Abstract][Full Text] [Related]
22. Long-term outcome of upper urinary tract carcinoma in situ: effectiveness of nephroureterectomy versus bacillus Calmette-Guérin therapy.
Kojima Y; Tozawa K; Kawai N; Sasaki S; Hayashi Y; Kohri K
Int J Urol; 2006 Apr; 13(4):340-4. PubMed ID: 16734847
[TBL] [Abstract][Full Text] [Related]
23. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
Coplen DE; Marcus MD; Myers JA; Ratliff TL; Catalona WJ
J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
[TBL] [Abstract][Full Text] [Related]
24. [Squamous cell carcinoma of the renal pelvis after intrarenal bacillus Calmette-Guerin therapy for carcinoma in situ of upper urinary tract: a case report].
Uemura M; Mukai M; Fukuhara S; Kanno N; Nishimura K; Miyoshi S; Yoshida K; Kawano K; Inoue H; Nishimura K
Hinyokika Kiyo; 2002 Jun; 48(6):355-7. PubMed ID: 12166236
[TBL] [Abstract][Full Text] [Related]
25. Bacillus Calmette-Guérin perfusion therapy for carcinoma in situ of the upper urinary tract.
Yokogi H; Wada Y; Mizutani M; Igawa M; Ishibe T
Br J Urol; 1996 May; 77(5):676-9. PubMed ID: 8689109
[TBL] [Abstract][Full Text] [Related]
26. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
J Urol; 1986 Oct; 136(4):820-4. PubMed ID: 3761438
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-8 expression in the urine after bacillus Calmette-Guerin therapy: a potential prognostic factor of tumor recurrence and progression.
Thalmann GN; Dewald B; Baggiolini M; Studer UE
J Urol; 1997 Oct; 158(4):1340-4. PubMed ID: 9302115
[TBL] [Abstract][Full Text] [Related]
28. Upper tract transitional cell carcinoma following treatment of superficial bladder cancer with BCG.
Miller EB; Eure GR; Schellhammer PF
Urology; 1993 Jul; 42(1):26-30. PubMed ID: 8328123
[TBL] [Abstract][Full Text] [Related]
29. [Progression and recurrence in the prostate and upper urinary tract following intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer].
Wakabayashi Y; Okada Y; Mukumoto K; Hamaguchi A; Konishi T; Tomoyoshi T
Nihon Hinyokika Gakkai Zasshi; 1993 Dec; 84(12):2146-51. PubMed ID: 8309122
[TBL] [Abstract][Full Text] [Related]
30. New techniques for the administration of topical adjuvant therapy after endoscopic ablation of upper urinary tract transitional cell carcinoma.
Patel A; Fuchs GJ
J Urol; 1998 Jan; 159(1):71-5. PubMed ID: 9400440
[TBL] [Abstract][Full Text] [Related]
31. Durable response of a carcinoma in situ of the renal pelvis to topical bacillus Calmette-Guerin.
Herr HW
J Urol; 1985 Sep; 134(3):531-2. PubMed ID: 4032555
[TBL] [Abstract][Full Text] [Related]
32. Percutaneous bacillus Calmette-Guerin perfusion of the upper urinary tract for carcinoma in situ.
Studer UE; Casanova G; Kraft R; Zingg EJ
J Urol; 1989 Oct; 142(4):975-7. PubMed ID: 2795755
[TBL] [Abstract][Full Text] [Related]
33. Topical instillation of BCG immunotherapy for biopsy-proven primary upper urinary tract carcinoma in situ: A single institution series and systematic review.
Fontanet S; Gallioli A; Baboudjian M; Huguet J; Territo A; Gaya JM; Gavrilov P; Izquierdo P; Verri P; Algaba F; Palou J; Breda A
Urol Oncol; 2023 Jun; 41(6):274-283. PubMed ID: 36526527
[TBL] [Abstract][Full Text] [Related]
34. Sequential endoluminal gemcitabine and docetaxel vs. Bacillus Calmette-Guérin for the treatment of upper tract carcinoma in situ.
McElree IM; Mott SL; Hougen HY; Packiam VT; O'Donnell MA; Steinberg RL
Urol Oncol; 2024 Jul; 42(7):221.e9-221.e16. PubMed ID: 38609747
[TBL] [Abstract][Full Text] [Related]
35. Positive urinary cytology following a complete response to intravesical bacillus Calmette-Guerin therapy: pattern of recurrence.
Schwalb MD; Herr HW; Sogani PC; Russo P; Sheinfeld J; Fair WR
J Urol; 1994 Aug; 152(2 Pt 1):382-7. PubMed ID: 8015076
[TBL] [Abstract][Full Text] [Related]
36. Assessing treatment response after induction Bacillus Calmette-Guerin for carcinoma in situ of the urinary bladder: can post-induction random bladder biopsies be avoided?
Smith PJ; Lotan Y; Raj GV; Sagalowsky AI; Margulis V
Cytopathology; 2014 Apr; 25(2):108-11. PubMed ID: 23551700
[TBL] [Abstract][Full Text] [Related]
37. In situ transitional cell carcinoma involvement of prostatic urethra: bacillus Calmette-Guérin therapy without previous transurethral resection of the prostate.
Palou J; Xavier B; Laguna P; Montlleó M; Vicente J
Urology; 1996 Apr; 47(4):482-4. PubMed ID: 8638354
[TBL] [Abstract][Full Text] [Related]
38. Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors.
Kavoussi LR; Torrence RJ; Gillen DP; Hudson MA; Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
J Urol; 1988 May; 139(5):935-40. PubMed ID: 3361667
[TBL] [Abstract][Full Text] [Related]
39. Clinical outcomes of bacillus Calmette-Guérin instillation therapy for carcinoma in situ of urinary bladder.
Takenaka A; Yamada Y; Miyake H; Hara I; Fujisawa M
Int J Urol; 2008 Apr; 15(4):309-13. PubMed ID: 18380817
[TBL] [Abstract][Full Text] [Related]
40. Complications of intracavitary bacillus Calmette-Guerin after percutaneous resection of upper tract transitional cell carcinoma.
Bellman GC; Sweetser P; Smith AD
J Urol; 1994 Jan; 151(1):13-5. PubMed ID: 8254791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
